
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 11, 2014
ARQULE, INC.
(Exact Name of Issuer as Specified in Charter)
Delaware 000-21429 04-3221586 (State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification No.)
19 Presidential Way
Woburn, MA

ARQULE INC Form 8-K

November 12, 2014



Section 8 — Other Events
Item 8.01 Other Events.
On November 11, 2014, ArQule, Inc. (the "Registrant") issued a press release announcing a collaboration with the National Institutes of Health for the clinical development of ARQ 092, an orally available, selective small molecule inhibitor of AKT, in Proteus syndrome. The press release is furnished as Exhibit 99.1 hereto and incorporated herein by reference.
Section 9 – Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
Exhibit 99.1 Text of press release dated November 11, 2014 reporting clinical status updates.
2

## **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ARQULE, INC. (Registrant)

/s/ Peter S. Lawrence Peter S. Lawrence President and Chief Operating Officer

November 11, 2014

3